Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a real-world retrospective study. - Gao J; Xu J; He Y; Zong D; Jin T; He X (Frontiers in oncology, 2025)